ライフサイエンスコーパス: disease

1 -of-function mutations associated with human disease.

2 ing alone and in combination, confer risk of disease.

3 ging and those of lifestyle, environment and disease.

4 syndrome, such as non-alcoholic fatty liver disease.

5 able to induce long-term protection against disease.

6 nt to CD81's varied roles in both health and disease.

7 ars in patients with complex coronary artery disease.

8 from a clinicomolecular diagnosis of genomic disease.

9 wel syndrome are available to those with the disease.

10 tifying genetic anomalies linked to clinical disease.

11 A1 axis may play a role in inflammatory skin disease.

12 t modifiable risk factors for cardiovascular disease.

13 d cells (RBCs) during the blood stage of the disease.

14 er or predisposing factors for chronic liver disease.

15 or diagnosis and treatment of valvular heart disease.

16 ostasis, lung inflammation and immunological disease.

17 se metabolism, contributes to cardiovascular disease.

18 hysiological processes and are implicated in disease.

19 not resolved in due course becomes a chronic disease.

20 contributed to the development of overt skin disease.

21 s AEs can occur in those with advanced liver disease.

22 neth cell lysozymes in patients with Crohn's disease.

23 DAC and can be used to potentially downstage disease.

24 hralgias in acute and convalescent filovirus disease.

25 otect against invasive group B meningococcal disease.

26 ocyte function and dysfunction in health and disease.

27 e, select co-usage elevated the risk of oral disease.

28 xin (PODXL) are associated with human kidney disease.

29 s of retinal injury and retinal degenerative disease.

30 lerability for patients living with indolent disease.

31 mortality during antiretroviral-treated HIV disease.

32 lymphohistiocytosis, and chronic active EBV disease.

33 at lower doses (<5 mg) in 6 immune-mediated diseases.

34 echanisms involved in more common autoimmune diseases.

35 any individuals with these neurodegenerative diseases.

36 odocyte injury and proteinuria in glomerular diseases.

37 atients with TRPV4-related neurodegenerative diseases.

38 s, dermatitis, infection, and malignant skin diseases.

39 ental conditions and emerging pathogen-based diseases.

40 rant activation can lead to autoinflammatory diseases.

41 uding inflammatory, neurological, and immune diseases.

42 ciated tissue damage in chronic inflammatory diseases.

43 ities more vulnerable to vaccine-preventable diseases.

44 ice and humans with infections or autoimmune diseases.

45 prophylactic value for retinal degenerative diseases.

46 et TMPRSS6 to treat anemias and iron-related diseases.

47 potential for the treatment of inflammatory diseases.

48 8 (95% CI 1.53-2.07) for peripheral arterial disease, 1.32 (95% CI 1.15-1.50) for cerebrovascular dis

49 isease (18 with typical amnestic Alzheimer's disease, 17 with posterior cortical atrophy and 22 with

50 f 57 participants diagnosed with Alzheimer's disease (18 with typical amnestic Alzheimer's disease, 1

51 h as 78% in patients with inflammatory bowel disease(2).

52 irst evaluated in a pilot study (Alzheimer's disease = 20, control = 20), then in a second cohort whe

53 sponsible for the development of coronavirus disease 2019 (COVID-19) in infected individuals, who can

54 The spread of coronavirus disease 2019 (COVID-19) in Italy prompted drastic measur

55 Coronavirus disease 2019 (COVID-19) is a global public health proble

56 The coronavirus disease 2019 (COVID-19) pandemic has claimed the lives o

57 latform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antivira

58 ontribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

59 nts were admitted to the ICU for coronavirus disease 2019 out of 1,788 severe acute respiratory syndr

60 ging aspects of care in managing coronavirus disease 2019 patients, current and anticipated resource

61 hydronephrosis and/or high-grade upper tract disease(3-5).

62 biomarker criteria were applied (Alzheimer's disease = 37, control = 45), and finally in a third coho

63 18F-GTP1 tau PET was evaluated (Alzheimer's disease = 38, control = 11).

64 rsus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients undergoing metabolic

65 6 months for signs and symptoms of diarrheal disease, acute respiratory illness, and anemia.

66 otein that plays a major role in Alzheimer's disease (AD) and other tauopathies.

67 Alzheimer's disease (AD) causes unrelenting, progressive cognitive i

68 ) and amyloid beta accumulation in Alzheimer disease (AD), but to the knowledge of the authors the as

69 function plays a central role in Alzheimer's disease (AD), since it drives the cognitive decline.

70 in the onset and progression of Alzheimer's disease (AD).

71 ates in autosomal dominant polycystic kidney disease (ADPKD).

72 have a notable increase in the risk for this disease after menopause and typically develop coronary h

73 Challenges to the prevention of severe disease after virus infection include both a paucity of

74 h histopathologic attributes associated with disease aggressiveness in GBM, particularly tumor infilt

75 rtension, hyperlipidemia, and chronic kidney disease (all p < 0.001).

76 ith hypertension or with mortality or severe disease among patients diagnosed as having COVID-19.

77 ous serum-based eye drops for severe dry eye disease and 4 studies of persistent epithelial defect.

78 riation in these SEs may contribute to human disease and altered immunity.

79 e recently identified as causing Parkinson's disease and amyotrophic lateral sclerosis/frontotemporal

80 disease onset potently blocks progression of disease and further alpha-motoneuron degeneration.

81 the greatest risk factor for cerebrovascular disease and its subsequent effects.

82 attainment (schooling years) on a variety of disease and life-expectancy outcomes.

83 veal new insights into mechanisms of cardiac disease and serve as a test bed for drug screening.

84 Their activity is frequently deregulated in disease and targeting this class of proteins is a major

85 at may favor the development of cryptococcal disease and the fungal dissemination to the CNS.

86 ined incident dementia including Alzheimer's disease and vascular dementia, analyzing data from parti

87 s detection in the field of cancer and other diseases and demonstrate how nanobiosensors could enhanc

88 tive ingredients in order to protect against diseases and to develop healthy diets.

89 1.32 (95% CI 1.15-1.50) for cerebrovascular disease, and 1.93 (95% CI 1.47-2.53) for abdominal aorti

90 has been reported between RA and periodontal disease, and Porphyromonas gingivalis, a known driver of

91 etween amnestic and non-amnestic Alzheimer's disease, and receiver operating characteristic curve ana

92 familial hyperparathyroidism, multiglandular disease, and renal failure were excluded.

93 with metabolic disorders, neurodegenerative diseases, and aging.

94 s been used successfully in a broad range of diseases, and, more recently, this technique has gained

95 = 1.54 [95% CI = 1.21-1.97]; and autoimmune disease aOR = 1.68 [95% CI = 1.36-2.07]).

96 measures adopted to slow the transmission of disease are decreasing the demand for imaging independen

97 AMs) in human lung and their contribution to disease are poorly mapped out.

98 Retinal diseases are frequently characterized by the accumulatio

99 Chronic, non-communicable diseases are now recognised as diseases that need to be

100 Fungal diseases are responsible for the deaths of over 1.5 mill

101 predispose to atherosclerotic cardiovascular disease (ASCVD).

102 d at least one full-scheduled post-treatment disease assessment.

103 ted the findings of the field and greenhouse disease assessments.

104 ur ability to elucidate molecular drivers of disease-associated dysbiosis across the microbiota.

105 tatus, and the first database recording 1218 disease-associated genetic mutations that may function t

106 udy and analysed the most recent Parkinson's disease-associated genetic risk score to detect genetic

107 unctions in the nucleus and that Parkinson's disease-associated Parkin mutants, ParkinR42P and Parkin

108 ia, including Ruminococcus gnavus, a Crohn's disease-associated pathobiont.

109 into the molecular basis for malfunction of disease-associated XPA missense mutations, and contribut

110 DA can effectively predict potential circRNA-disease associations and provide highly credible candida

111 2 cytokine with important roles in allergic diseases, asthma, and tissue fibrosis.

112 Patients present with severe disease at a relatively early age and most (67%) have sl

113 ation may benefit neurons from spine loss in diseases, at least, in those with F1Fo ATP synthase defe

114 , 8.38 to 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

115 r patient-derived xenograft model leading to disease attenuation and prolonged survival.

116 were analyzed to calculate the proportion of disease attributed to individual HAdV serotypes (i.e., a

117 lopmental pathways, implicating them in many diseases besides cancer, including lung, renal, and neur

118 lipids impact development, homeostasis, and disease, but links between specific dietary fats and cel

119 on of patients with unstable coronary artery disease (CAD), and their recruitment to inflamed arterie

120 the health of patients with coronary artery disease (CAD).

121 The study of familial autoimmune diseases can reveal pathophysiological mechanisms involv

122 a gravis (MG) is a neuromuscular, autoimmune disease caused by autoantibodies that target postsynapti

123 is characterized by premature cardiovascular disease caused by markedly elevated levels of low-densit

124 opathy, X-linked (IPEX) syndrome is a lethal disease caused by mutations in a transcription factor cr

125 Lyme disease, caused by some Borrelia burgdorferi sensu lato,

126 argest receptor-group of hand-foot-and-mouth disease causing viruses, which includes CV-A10.

127 genome in 886 index cases of PID found that disease-causing mutations in known genes that are implic

128 Despite its relevance as a disease-causing serotype, the associated capsular polysa

129 en healthy controls and patients with celiac disease (CD).

130 modern lifestyle in abetting Coronary Heart Diseases (CHD) have mostly focused on deterrent health f

131 cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF

132 the involved vascular-sensing mechanisms and disease consequences remain unclear.

133 tory of clonotypes and traceability over the disease course.

134 on plays an important role in cardiovascular disease (CVD) development.

135 Cardiovascular disease (CVD) is the leading cause of death in women, wh

136 ciated with increased risk of cardiovascular disease (CVD).

137 mpairment who did not convert to Alzheimer's disease dementia.

138 o a positive association between periodontal disease, dental caries, and cocaine use, select co-usage

139 However, the impacts on post-transmission disease development and infectiousness in contact indivi

140 ed pediatric patients correlates with severe disease development.

141 d as a therapeutic target for cardiovascular disease due to its ability to remodel cardiac tissue and

142 gnitude of anorexia (e.g., via drugs) affect disease dynamics and virulence evolution.

143 Our study links DNA methylation to disease endpoints via intermediate proteomics phenotypes

144 nostic for the growth rate of any infectious disease epidemic.

145 testing (e.g., HIV, diabetes, chronic kidney disease, etc.) were identified from physician claims, ho

146 of HtrA1 in the eye and its contribution to disease etiologies remain undefined.

147 herapy had a lower incidence of tuberculosis disease even when they had been exposed to an index pati

148 accelerating tempo of epizootic and zoonotic disease events has made it seem as if disease is on the

149 rrent models only partially recapitulate key disease features, and pathophysiology is poorly understo

150 s and differences between MIS-C and Kawasaki disease, focusing on their epidemiology, aetiology and p

151 apy was significantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92

152 tize RAMS11 due to its association with poor disease-free survival and promotion of aggressive phenot

153 uppressive regimens have been used with poor disease-free survival at long-term follow-up.

154 P/LP variants who were predicted to develop disease (G+).

155 Macroscopic disease: Gastric lesions were multiple: 38%, single: 62%

156 We report state-of-the-art results on 12 disease-gene associations and on a time-stamped benchmar

157 y Dnmt3a and Dnmt3b were enriched for kidney disease genetic risk loci.

158 n 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespread cortical regions.

159 ommendations from the earlier valvular heart disease guidelines have been updated with new evidence a

160 endent metabolite, worsens graft-versus-host disease (GVHD).

161 rticular, the central role of B cells in the disease has been demonstrated by both the robust clinica

162 hat result in organ dysfunction in aging and disease have often not been clarified.

163 f hemophilia A and B, or with von Willebrand disease, have an increased risk of bleeding during pregn

164 Inflammatory bowel disease (IBD) is a common chronic inflammatory condition

165 mining susceptibility to and severity of RSV disease in adults have not been well defined.

166 se serious infections and inflammatory bowel disease in glycogen storage disease type Ib (GSD-Ib).

167 dispose individuals to be vulnerable to lung disease in later life.

168 There is a growing burden of cardiometabolic disease in many parts of the world.

169 ible increased risk of acute cerebrovascular disease in patients with dual infection merits further i

170 Genetic risk for a disease in the population may be represented as a geneti

171 one of the most common single gene familial diseases in humans.

172 prescribed therapeutic options for sinonasal diseases in humans.

173 Podocytopathies are kidney diseases in which direct or indirect podocyte injury dri

174 de the climate-health outlook about possible disease incidence at least 2 weeks in advance for any lo

175 h the categorical probabilistic forecasts of disease incidences, this early health warning system is

176 Chronic inflammatory diseases including human immunodeficiency virus infectio

177 ysfunctions, which lead to several metabolic diseases including obesity or type 2 diabetes.

178 vaccines for some of the world's most deadly diseases, including AIDS and malaria.

179 al for physiology and can go awry in various diseases, including cancer.

180 (EBV) is associated with a number of T-cell diseases, including some peripheral T-cell lymphomas, he

181 stress has adverse effects on various human diseases, including those of the cardiovascular system.

182 of EPCR appeared to associate with increased disease index of the experimental colitis in mice.

183 likely results from distinct biological and disease initiation and progression events associated wit

184 Parkinson's disease is caused by a loss of dopaminergic input from t

185 The disease is confined mainly to a central retinal region c

186 The severity of COVID-19 lung disease is higher in the elderly and people with pre-exi

187 The pathophysiology of disease is not fully understood, and it may vary by pres

188 onotic disease events has made it seem as if disease is on the rise.

189 ls for Stargardt are currently underway, the disease is typically slowly progressive, and objective,

190 The disease is very likely to be underdiagnosed.

191 ntify key network modules related to complex diseases like COPD.

192 xcess extracellular matrix deposition in the diseased liver and as such are important in the progress

193 herapeutic targets of late-onset Alzheimer's Disease (LOAD), we performed an integrative network anal

194 esions in different species or that the same disease may arise in different species under different e

195 al research opportunity for uncovering novel disease mechanisms and therapies.

196 mune function and the development of CF lung disease.Methods: We performed single-cell RNA sequencing

197 tream applications such as drug repurposing, disease modeling and gene function prediction.

198 on, demonstrating their future potential for disease modeling and therapeutic screening applications.

199 The integrative disease-modelling strategy may reveal new insights into

200 ic alterations in schizophrenia and relevant disease models and discuss their putative origin.

201 Several metabolic disease models have shown that dysregulation of sarcopla

202 ring the healthcare system for the advent of disease-modifying therapies against AD is imperative.

203 Accurate disease monitoring is essential after transarterial chem

204 f dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases, or epilepsy.

205 atrophy and genetic risk factors for celiac disease must undergo endoscopic evaluation after 1-3 yea

206 Disease-mutations cluster within the conserved N-Lip and

207 ples were collected from healthy (n = 5) and diseased (n = 5) sites of each patient.

208 The noncommunicable disease (NCD) burden in Kenya is not well characterized,

209 nt and Imaging Correlates in End Stage Renal Disease, NCT01883349.

210 severe infection included pre-existing renal disease (odds ratio [OR], 7.4; 95% CI, 2.5-22.0), oxygen

211 Fusarium head blight (FHB) is a severe disease of wheat (Triticum aestivum L.).

212 mmune, metabolic, neoplastic, and infectious diseases of the intestine and mitigate the particular he

213 l analyses offers the potential of detecting diseases of the retina at earlier stages before irrevers

214 The primary outcome was the severity of lung disease on admission chest radiographs, measured by usin

215 re to minimize the impact of metastatic bone disease on physical functioning.

216 Disease onset in females occurred across all age groups,

217 Treatment after disease onset potently blocks progression of disease and

218 g increased disability), at 6-10 years after disease onset, assessed with a linear mixed-effects mode

219 ith LEMS, occurring within three months from disease onset, were collated to produce a DELTA-P score

220 Whether this dysbiosis contributes to disease or merely represents a bystander effect remains

221 disorders and injuries, e.g., in Parkinson's disease or traumatic brain injury (TBI), and hence it wi

222 ts can be attributed to metastatic spread of disease or tumor recurrence after initial treatment.

223 , and mechanisms by which variants can cause diseases or alter phenotypic traits.

224 1.22, 95% CI 1.12-1.34) and ischaemic heart disease (OR 1.30, 95% CI 1.15-1.47).

225 l (CI), 1.2-3.4, P = 0.009), coronary artery disease (OR, 1.9; 95% CI, 1.1-3.7; P = 0.04), and respir

226 ular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individual com

227 s disease, Parkinson's disease, motor neuron diseases, or epilepsy.

228 wnstream gene expression-based prediction of disease outcome.

229 reated nonhuman primates had similar overall disease outcomes compared with untreated control nonhuma

230 al life experiences and offspring health and disease outcomes.

231 s (n = 4,184 subjects free of cardiovascular disease), PA was measured by waist-secured accelerometer

232 Patients with peripheral artery disease (PAD) have a higher risk of major adverse cardio

233 Variation in risk factors across host-disease pairs suggests that either different pathogens c

234 erm increased risks of dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases, or

235 developing a more profound understanding of disease pathogenesis and ultimately targeted therapies.

236 of IFI16 and AIM2 contribute to periodontal disease pathogenesis may lead to treatment options that

237 virus and innate receptors that may underlie disease pathogenesis.

238 or the treatment of anemia in chronic kidney disease patients and may also be beneficial for the trea

239 No more than 42% of Alzheimer's disease patients had atrophy at any given location acros

240 pecifically, the age at onset of Parkinson's disease patients with pathogenic/likely pathogenic varia

241 Parkinson's disease (PD) pathogenesis may involve the epigenetic con

242 are a major cause of early-onset Parkinson's disease (PD).

243 might help to gain further insights into the disease process.

244 f brain tissue, raising the possibility that disease progression could potentially be slowed by disru

245 ordering patients along a trajectory of LOAD disease progression from brain transcriptomic data.

246 f age-related macular degeneration (AMD) and disease progression, but the precise biological function

247 esponses to SARS-CoV-2 and the predictors of disease progression.

248 BIN1, to ameliorate synaptic dysfunction and disease progression.

249 erstand the molecular interactions governing disease progression.

250 n between gingivitis and obesity may exhibit disease reciprocity in which activated neutrophils are m

251 Experimental methods to determine disease related miRNAs are time consuming and costly.

252 by pull-down target profiling, and to rescue disease-relevant splicing of tau pre-mRNA in a variety o

253 any gaps in our understanding of Alzheimer's disease remain despite intense research efforts.

254 Overall survival in patients with relapsed disease remains poor, and thus novel therapeutic approac

255 echanism by which the UBQLN2 mutations cause disease remains unclear.

256 rplay of components involved in multifaceted disease responses, like atherosclerosis.

257 in determining chronic obstructive pulmonary disease risk and severity is controversial.Objectives: T

258 In the Coronary Artery Disease Risk Development in Young Adults study, a cohort

259 cents and are associated with cardiovascular disease risk factors, HsCRP and Ox-LDL.

260 % CI, 1.02, 2.72, P = .04), perceived kidney disease risk following donation (aOR, 1.68; 95% CI, 1.03

261 ated with reduction of an inflammatory bowel disease risk gene ATG16L1 and Paneth cell lysozymes in p

262 variants individually have small effects on disease risk, GWAS provide a powerful opportunity to exp

263 oning, and act as intermediate biomarkers of disease risk.

264 cell type expression profiles with specific disease risk.

265 ss an unmet need for this difficult to treat disease.See related article by Gonda et al., p.

266 nopause and typically develop coronary heart disease several years later than men.

267 re specifically for COVID-19 to help predict disease severity and mortality.

268 The core disease signature revealed remarkably strong connections

269 orticoids have been widely used in rheumatic diseases since they became available over 60 years ago.

270 to aggressive and invasive tumors with high disease-specific mortality.

271 re extensive lymphadenectomy leads to better disease-specific survival in patients treated with surge

272 uggested novel roles of EGR1 and SGK1 in the disease state.

273 genetic perturbations, drug treatments, and disease states.

274 ncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions.

275 may also be beneficial for the treatment of diseases such as chronic inflammation and ischemia-reper

276 the ability to detect and track outbreaks of diseases such as COVID-19, investigate transmission chai

277 ve when treating major depressive disorder-a disease that afflicts ~20% of the world's population.

278 Cancer, a disease that is prone to drug resistance, is in principl

279 apeutic target for obesity-related asthma, a disease that is suboptimally responsive to current thera

280 -communicable diseases are now recognised as diseases that need to be addressed in such crises.

281 orders are a group of nine neurodegenerative diseases that share a common genetic cause, which is an

282 Due to late diagnosis of this disease, the mortality of this condition is very high.

283 e the deadliest animals on Earth because the diseases they transmit claim at least a million human li

284 ess and address patient activation in kidney disease to facilitate best practices for supporting pati

285 flammatory bowel disease in glycogen storage disease type Ib (GSD-Ib).

286 nd within examiners in the diagnosis of plus disease using DL.

287 The incidence of major cardiovascular disease was associated with increased risk of ESKD, with

288 Thromboembolic disease was contextualized by premortem AC among consecu

289 on of the digestive tract tumors of 2010 the disease was grouped under a heterogeneous and imprecise

290 ur understanding of the etiology of blinding diseases, we used single-cell RNA-sequencing (scRNA-seq)

291 ast 150 cells per microliter, and autoimmune disease were associated with frequent AECRS with statist

292 No deaths or cases of inflammatory bowel disease were reported.

293 CMV-infection and -disease were successfully managed with letermovir.

294 important insights about the cause of these diseases, which can help accelerate new prevention strat

295 nformation can explain phenotypes of genetic diseases, which cannot be obtained by transcript informa

296 with various types of laminopathy-containing diseases, which have features of accelerated aging and o

297 the reading ability in patients with corneal diseases, which is a crucial part of visual rehabilitati

298 ICE ADVICE 6: Patients with suspected celiac disease who are seronegative but have villous atrophy an

299 rials in children with high-risk MYCN-driven disease, with limited ability to evaluate conventional p

300 s for the largest burden of non-communicable diseases worldwide.